Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients
16 February 2023 - 5:15PM
Business Wire
Eurofins Viracor ExPeCT™ CAR-T multiplexed
quantitative real-time PCR (qPCR) assay provides a powerful
diagnostic tool to monitor and optimise CAR-T therapy involving
patients with pre-B cell acute lymphoblastic leukemia and B cell
lymphomas
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Viracor LLC, part of the Eurofins network of companies,
and a leader in testing for infectious disease, immunology, and
allergy, announces the launch of a ground-breaking test that can
assess the expansion and persistence of Chimeric Antigen Receptor
T-Cell (CAR-T) therapy in patients with pre-B cell acute
lymphoblastic leukemia and B cell lymphomas.
The test, based on a method developed by Eurofins Viracor, is
designed to help clinicians better understand how CAR-T therapy is
performing for their patients. CAR-T therapy is a revolutionary
form of immunotherapy that uses genetically engineered T-cells to
attack cancer cells and has shown promising results in treating a
variety of cancers.
Research has demonstrated that the persistence and expansion of
CAR-T therapy are important indicators of how long the therapy is
likely to remain effective in the patient. The test is designed to
provide clinicians with an accurate and comprehensive assessment of
the CAR-T cell population in the patient’s body and may offer
insights to therapy effectiveness.
The launch of this test marks an important step forward in the
evaluation and management of CAR-T therapy in cancer patients. It
is expected to be a valuable tool in helping clinicians to make
more informed decisions about the best course of treatment for
their patients.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With over 61,000 staff across a decentralised and
entrepreneurial network of 940 laboratories in 59 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products. The Group’s objective is to provide
its customers with high-quality services, innovative solutions and
accurate results on time. Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230215005664/en/
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024